Volume 2.43 | Nov 18

Mammary Cell News 2.43 November 18, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY


MicroRNA Controls Mammary Gland Development in Mice  ShareThis
As a team of scientists have discovered, in the case of breast development, hormones and proteins do not account for the full story. They have shown that tiny ribonucleic acid molecules play a key role in this process. [Press release from the Max Planck Society discussing online prepublication in Nature Genetics]

ALDEFLUORBreastCSC_645x110



SPECIAL FEATURE

Interested in recruiting talented individuals? Post your career opportunities in Mammary Cell News at no cost. Contact us at [email protected]

Follow us on Twitter! @MammaryCell



SCIENCE NEWS

Scientists Identify Potential New Target for Treating Triple Negative Breast Cancer
Researchers in Dublin (Ireland) have found that triple negative breast cancer (TNBC) cells respond to compounds that disrupt the signaling processes of another receptor, EGFR (epidermal growth factor receptor), high levels of which are expressed in TNBC. [Press release from European CanCer Organization (ECCO) discussing data presented at the 22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium on Molecular Targets and Cancer Therapeutics]

Erythropoietin Counteracts Breast Cancer Treatment With Herceptin
Researchers find erythropoiesis-stimulating drugs cut response to human epidermal growth factor receptor-2 targeted therapy. [Press release from The University of Texas MD Anderson Cancer Center discussing online prepublication in Cancer Cell]

Joint Pain Linked to Breast Cancer Drug Not Inflammatory Arthritis or Autoimmune Disease
A new study suggests joint complaints attributed to aromatase inhibitors, popular breast cancer drugs, are not associated with inflammatory arthritis or autoimmune disease. [Press release from Georgetown University Medical Center discussing data presented at the 74th Annual Scientific Meeting of the American College of Rheumatology]

Request a Free Sample  
New Defined Medium – EpiCult®-C
For Robust Growth of Human Mammary Luminal and Myoepithelial Cells
by STEMCELL Technologies
 
 
REQUEST A FREE SAMPLE STEMCELL Technologies Inc
 



CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

miR-212 and miR-132 are Required for Epithelial Stromal Interactions Necessary for Mouse Mammary Gland Development
Here, researchers show that the microRNA-212/132 family (which comprises miR-212 and miR-132) is indispensable during the development of the mammary glands in mice, particularly for the regulation of the outgrowth of the epithelial ducts. [Nat Genet]

Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells Via Jak2-Mediated Src Activation and PTEN Inactivation
Researchers identified Jak2-mediated activation of Src and inactivation of PTEN as underlying mechanisms through which recombinant human erythropoietin antagonizes trastuzumab-induced therapeutic effects. [Cancer Cell]

BRCA2 Acts as a RAD51 Loader to Facilitate Telomere Replication and Capping
Here, researchers show that BRCA2 associates with telomeres during the S and G2 phases of the cell cycle and facilitates the loading of RAD51 recombinase onto telomeres. [Nat Struct Mol Biol]

Specific Posttranslational Modification Regulates Early Events in Mammary Carcinoma Formation
The expression of an enzyme, GnT-V, that catalyzes a specific posttranslational modification of a family of glycoproteins, namely a branched N-glycan, is transcriptionally up-regulated during breast carcinoma oncogenesis. To determine the molecular basis of how early events in breast carcinoma formation are regulated by GnT-V, researchers studied both the early stages of mammary tumor formation by using 3D cell culture and a her-2 transgenic mouse mammary tumor model. [Proc Natl Acad Sci USA]

The Tumour Suppressor C/EBP(Delta) Inhibits FBXW7 Expression and Promotes Mammary Tumour Metastasis
Here, researchers demonstrate a tumour suppressor function of C/EBP(delta) using transgenic mice overexpressing the Neu/Her2/ERBB2 proto-oncogene in the mammary gland. [EMBO J]

p53-Mediated Transcriptional Regulation and Activation of the Actin Cytoskeleton Regulatory RhoC to LIMK2 Signaling Pathway Promotes Cell Survival
Researchers show that RhoC and LIM kinase 2 (LIMK2) are direct p53 target genes induced by genotoxic agents. [Cell Res]

MicroRNA-221/222 Confers Breast Cancer Fulvestrant Resistance by Regulating Multiple Signaling Pathways
To examine a possible role(s) of aberrantly expressed microRNAs in acquired fulvestrant resistance, researchers compared antiestrogen-resistant and -sensitive breast cancer cells, revealing the overexpression of miR-221/222 in the selective estrogen receptor downregulator-resistant cell lines. [Oncogene]

Controlled Extracellular Matrix Degradation in Breast Cancer Tumors Improves Therapy by Trastuzumab
In immunohistochemical studies of tumor sections from breast cancer patients and xenografts, researchers observed colocalization of extracellular matrix proteins and Her2/neu, a tumor-associated antigen that is the target for the widely used monoclonal antibody trastuzumab (Herceptin). [Mol Ther]

2-Tellurium-Bridged Beta-Cyclodextrin, a Thioredoxin Reductase Inhibitor, Sensitizes Human Breast Cancer Cells to TRAIL-Induced Apoptosis Through DR5 Induction and NF-KappaB Suppression
In the present study, researchers reported that 2- tellurium-bridged beta-cyclodextrin sensitized Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant human breast cancer cells and xenograft tumors to undergo apoptosis. [Carcinogenesis]

Steroid Receptor Coactivator 1 Deficiency Increases MMTV-Neu Mediated Tumor Latency and Differentiation Specific Gene Expression, Decreases Metastasis, and Inhibits Response to PPAR Ligands
The results indicate that histone acetyltransferases play key roles in mammary tumorigenesis and response to anti-proliferative therapies. [BMC Cancer]

CLINICAL RESEARCH

Identification of a Low-Risk Subgroup of HER-2-Positive Breast Cancer by the 70-Gene Prognosis Signature
The 70-gene prognosis signature is an independent prognostic indicator that identifies a subgroup of HER-2-positive early breast cancer with a favourable long-term outcome. [Br J Cancer]



INDUSTRY NEWS

Orbital Therapy Receives Grant for Self-Shielded Radiotherapy Device
Orbital Therapy has been awarded a $244,479 grant for its breast cancer research project as part of the U.S. government’s Therapeutic Discovery Project. [Orbital Therapy, LLC Press Release]

NCI Awards $11.5 Million to Fred Hutchinson Cancer Research Center to Lead Breast Cancer Research Consortium
The National Cancer Institute has awarded $11.5 million to Fred Hutchinson Cancer Research Center to lead a five-year, Seattle-based breast cancer research consortium. [Fred Hutchinson Cancer Research Center Press Release]



POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)



EVENTS (Listed by Date)

5th Annual Stem Cell Meeting on the Mesa
December 7, 2010
La Jolla, United States

American Association for Cancer Research (AACR) 33rd Annual San Antonio Breast Cancer Symposium
December 8-12, 2010
San Antonio, United States

NEW  The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
December 17-19, 2010
Guangzhou, China

Keystone Symposia: Epithelial Plasticity and Epithelial to Mesenchymal Transition
January 21-26, 2011
Vancouver, Canada

5th Annual Stem Cells and Regenerative Medicine World Congress
January 24-25, 2011
San Diego, United States

Molecular Medicine Tri-Conference: Inaugural Circulating Tumor Cells for Cancer Detection, Diagnosis, Prognosis and Treatment
February 23-25, 2011
San Francisco, United States

American Association for Cancer Research (AACR) Targeting PI3K/mTOR Signaling in Cancer
February 24-27, 2011
San Francisco, United States

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

28th Annual Miami Breast Cancer Conference
March 9-12, 2011
Miami, United States

MENA Oncology Conference
March 11-12, 2011
Cairo, Egypt

United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

National Cancer Institute (NCI) Cancer Research Imaging Camp
June 19-24, 2011
St. Louis, United States

4th Annual Advances in Biodetection & Biosensors Conference and Exhibition
June 30-July 1, 2011
Hamburg, Germany

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)


Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.
Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!



Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us